Targeting the Microbiome Could Improve Parkinson’s Therapy
Research identifies enzymes produced by two different bacterial species that work together to digest L-Dopa in the human gut. Blocking one of these bacterial enzymes could significantly boost the drug’s efficacy in these patients.